Today, the American Consumer Institute (ACI) send a letter to the Senate and House Leadership highlighting keys ways for Congress to lower drug prices for patients. Among ACI’s suggestions were the streamlining of regulations that impede market entry for generic and biosimilar drugs. In addition to increasing price competition, the letter recommends requiring Pharmacy Benefit Managers to pass the manufacturers’ rebates they receive along to consumers in the form of lower prices. These steps and others would heighten market competition, lower drug prices, and increase patients’ access to lifesaving drugs.

The letter is available here.